One of the biggest pharmaceutical firms in India and a pioneer in specialized generics is Sun Pharmaceutical Industries Ltd. The business is well-established in the US, India, and a number of emerging regions. Sun Pharma has managed to hold onto its position as a leading player in the global pharmaceutical sector by maintaining a strong product portfolio and a focus on research and development.
This article will examine Sun Pharma’s stock more closely and provide a thorough analysis of the company’s growth potential in the upcoming years. We’ll look at the major variables that could have an impact on the company’s success and give a detailed forecast of its share price from 2023 to 2030.
CLICK HERE TO KNOW:
TATA POWER COMPANY SHARE PRICE TARGET 2023 TO 2030: CAN TATA POWER REACH 2000 INR?
SUN PHARMA IN RECENT NEWS
- Sun Pharmaceutical has introduced a new medication for the treatment of dry eye disease.
- Following FDA directives, Sun Pharma is expected to face supply challenges from its Mohali plant.
SUN PHARMA SHARE PRICE TARGET 2023
| SUN PHARMA SHARE PRICE TARGET 2023 | Maximum Price | Minimum Price |
| April 2023 | ₹987.65 | ₹759.73 |
| May 2023 | ₹823.04 | ₹633.11 |
| June 2023 | ₹987.65 | ₹759.73 |
| July 2023 | ₹1,185.18 | ₹911.68 |
| August 2023 | ₹1,303.70 | ₹1,002.84 |
| September 2023 | ₹1,368.88 | ₹1,052.99 |
| October 2023 | ₹1,303.70 | ₹1,002.84 |
| November 2023 | ₹1,434.07 | ₹1,103.13 |
| December 2023 | ₹1,606.16 | ₹1,235.50 |
In April, the maximum target of ₹987.65 may be due to positive investor sentiment, while the minimum target of ₹759.73 may be due to industry competition or a slowdown in demand. May saw a decrease in targets, with the maximum target of ₹823.04 still indicating a positive outlook, while the minimum target of ₹633.11 suggested caution. June returned to the earlier market outlook of April. In July, a significant increase in targets may be due to positive news about the company or the industry, while in August, further increases in targets may be due to positive news or events related to the company. September displayed the highest targets in the table, with a maximum target of ₹1,368.88 indicating a very positive outlook. However, even in an optimistic scenario, the minimum target of ₹1,052.99 suggested some caution. October returned to an earlier market outlook, with the same targets as April.
SUN PHARMA SHARE PRICE TARGET 2024
| SUN PHARMA SHARE PRICE TARGET 2024 | Maximum Price | Minimum Price |
| January 2024 | ₹1,690.69 | 1037.03 |
| February 2024 | ₹1,899.65 | ₹1,583.04 |
| March 2024 | ₹1,999.63 | ₹1,625.72 |
| April 2024 | ₹1,817.85 | ₹1,398.35 |
| May 2024 | ₹1,514.87 | ₹1,165.29 |
| June 2024 | ₹1,817.85 | ₹1,398.35 |
| July 2024 | ₹1,545.17 | ₹1,197.81 |
| August 2024 | ₹1,699.69 | ₹1,348.96 |
| September 2024 | ₹1,784.67 | ₹1,372.83 |
| October 2024 | ₹2,099.62 | ₹1,615.09 |
| November 2024 | ₹2,204.60 | ₹1,695.84 |
| December 2024 | ₹2,248.69 | ₹1,729.76 |
Sun Pharmaceutical Industries Ltd’s share price targets for 2024 suggest a positive outlook for the company. The year starts with a wide range of targets, with a maximum of ₹1,690.69 and a minimum of ₹1,037.03 for January. The significant increase in the maximum target in February to ₹1,899.65 may be due to positive news or events related to the company. The share price targets for March and April are also optimistic, with a maximum target of ₹1,999.63 and ₹1,817.85, respectively. May sees a decrease in targets, with a maximum of ₹1,514.87 and a minimum of ₹1,165.29. The targets for June are the same as those for April, indicating a return to an earlier market outlook. July’s targets are also relatively conservative, with a maximum of ₹1,545.17 and a minimum of ₹1,197.81. The maximum target for August is ₹1,699.69, while the minimum target is ₹1,348.96. The targets for September see an increase in the maximum target to ₹1,784.67, while the minimum target remains relatively stable at ₹1,372.83. October sees a significant increase in both the maximum and minimum targets, with a maximum of ₹2,099.62 and a minimum of ₹1,615.09. The maximum target for November is even higher at ₹2,204.60, while the minimum target is ₹1,695.84. The year ends with a maximum target of ₹2,248.69 and a minimum of ₹1,729.76 in December. The maximum share price target for 2024 is ₹2,248.69, while the minimum target is ₹1,037.03.
CLICK HERE:
INDUSIND BANK SHARE PRICE TARGET 2023 TO 2030: CAN INDUSIND BANK REACH 5000 INR?
SUN PHARMA SHARE PRICE TARGET 2025
| SUN PHARMA SHARE PRICE TARGET 2025 | Maximum Price | Minimum Price |
| January 2025 | ₹2,293.66 | ₹1,764.36 |
| February 2025 | ₹2,414.38 | ₹1,857.22 |
| March 2025 | ₹2,535.10 | ₹1,950.08 |
| April 2025 | ₹2,263.48 | ₹1,741.14 |
| May 2025 | ₹2,057.71 | ₹1,582.85 |
| June 2025 | ₹2,263.48 | ₹1,741.14 |
| July 2025 | ₹2,155.70 | ₹1,658.23 |
| August 2025 | ₹2,245.52 | ₹1,727.32 |
| September 2025 | ₹2,357.79 | ₹1,813.69 |
| October 2025 | ₹2,499.26 | ₹1,922.51 |
| November 2025 | ₹2,674.21 | ₹2,057.08 |
| December 2025 | ₹2,727.69 | ₹2,098.23 |
In January, the maximum share price target was ₹2,293.66, which may have been due to positive investor sentiment, while the minimum target of ₹1,764.36 may have resulted from industry competition or a slowdown in demand. The share price target increased in February, March, and August, potentially indicating positive news or developments. The targets decreased in April and May, possibly reflecting concerns about performance or market conditions. September and October saw further increases, possibly due to strong earnings reports or partnerships. In November and December, the targets significantly increased, likely due to positive news or events related to the company or industry. The maximum target for December was ₹2,727.69, suggesting a continued bullish outlook for Sun Pharma’s shares in 2025. The minimum target for the year was ₹1,582.85, while the maximum target was ₹2,727.69.
SUN PHARMA SHARE PRICE TARGET 2026 TO 2030
| SUN PHARMA SHARE PRICE TARGET BY | Maximum Price | Minimum Price |
| 2026 | ₹1,909.39 | ₹1,336.57 |
| 2027 | ₹1,622.98 | ₹1,136.08 |
| 2028 | ₹2,921.36 | ₹2,044.95 |
| 2029 | ₹6,000.93 | ₹4,200.65 |
| 2030 | ₹6,682.85 | ₹4,678.00 |
Sun Pharmaceutical Industries Ltd’s share price target for the period of 2026 to 2030 shows a wide range of potential outcomes. In 2026, the maximum target is ₹1,909.39 while the minimum target is ₹1,336.57. This suggests that the share price may experience fluctuations during this year. In 2027, the maximum target decreases to ₹1,622.98, while the minimum target is ₹1,136.08. This may indicate a period of lower investor confidence or industry challenges. However, in 2028, the maximum target significantly increases to ₹2,921.36, suggesting a more bullish outlook. The minimum target is also higher at ₹2,044.95. In 2029, the maximum target reaches a high of ₹6,000.93, while the minimum target is ₹4,200.65. This indicates a potentially optimistic scenario for the company. Finally, in 2030, the maximum target is ₹6,682.85, while the minimum target is ₹4,678.00, suggesting a continuation of positive investor sentiment and a bullish outlook.
CLICK HERE:
AU SMALL FINANCE BANK SHARE PRICE TARGET 2023 TO 2030: CAN ASF BANK REACH 3000 INR?
FINANCIAL STRENGTH OF SUN PHARMA (2018 TO 2022)
| ANNUAL | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
| Total Revenue | 39,576.00 | 34,333.66 | 33,473.48 | 30,091.40 | 27,254.30 |
| Total Revenue Growth (%) | 15.27 | 2.57 | 11.24 | 10.41 | -14.65 |
| Total Expenses | 30,527.86 | 27,228.15 | 28,203.25 | 25,066.82 | 22,824.82 |
| Total Expenses Growth (%) | 12.12 | -3.46 | 12.51 | 9.82 | -0.26 |
| Profit after Tax (PAT) | 3,272.73 | 2,903.82 | 3,764.93 | 2,665.42 | 2,161.55 |
| PAT Growth (%) | 12.70 | -22.87 | 41.25 | 23.31 | -68.96 |
| Operating Profit Margin (%) | 23.73 | 21.63 | 16.97 | 19.19 | 18.72 |
| Net Profit Margin (%) | 8.46 | 8.66 | 11.46 | 9.17 | 8.18 |
| Basic EPS (₹) | 13.60 | 12.10 | 15.70 | 11.10 | 9.00 |
Sun Pharmaceutical Industries Ltd has demonstrated steady growth over the past five years as evidenced by their financial bank statement. The company’s total revenue has consistently increased from FY 2018 to FY 2022, with a maximum growth of 15.27% in FY 2022. Similarly, the company’s profit after tax (PAT) has also shown steady growth, with a maximum increase of 41.25% in FY 2020. However, the company experienced a decline in PAT in FY 2021 with a decrease of 22.87%. The operating profit margin has also increased from 18.72% in FY 2018 to 23.73% in FY 2022, indicating efficient cost management. Additionally, the basic earnings per share (EPS) has consistently increased over the past five years, with a maximum of ₹15.70 in FY 2020. Despite the company’s total expenses consistently increasing, they have managed to maintain a healthy net profit margin of around 8-9% over the past five years. Overall, Sun Pharmaceutical Industries Ltd has shown positive percentage growth in terms of revenue, profit, and EPS, indicating a positive trend in the company’s financial performance.
CLICK HERE FOR MORE:
IDFC FIRST BANK LTD SHARE PRICE TARGET: CAN IDFC BANK REACH 200 INR?
FAQ’s
What is Sun Pharmaceutical Industries Ltd?
Sun Pharmaceutical Industries Ltd is an Indian multinational pharmaceutical company headquartered in Mumbai, India. It specializes in the development and manufacturing of generic and branded drugs.
How has Sun Pharma’s revenue growth been over the years?
Sun Pharma’s revenue growth has been fluctuating over the years. In FY 2018, it saw a negative growth of -14.65%. However, in the following years, it saw a growth of 10.41%, 11.24%, 2.57%, and 15.27% in FY 2019, FY 2020, FY 2021, and FY 2022, respectively.
How has Sun Pharma’s PAT growth been over the years?
Sun Pharma’s PAT growth has also been fluctuating over the years. In FY 2018, it saw a negative growth of -68.96%. However, in the following years, it saw a growth of 23.31%, 41.25%, -22.87%, and 12.70% in FY 2019, FY 2020, FY 2021, and FY 2022, respectively.
What is the basic EPS of Sun Pharma in FY 2022?
The basic EPS of Sun Pharma in FY 2022 was ₹13.60.
What is the net profit margin of Sun Pharma in FY 2021?
The net profit margin of Sun Pharma in FY 2021 was 8.66%.
What is the operating profit margin of Sun Pharma in FY 2019?
The operating profit margin of Sun Pharma in FY 2019 was 19.19%.
CONCLUSION: SUN PHARMACEUTICAL INDUSTRIES LTD SHARE PRICE TARGET
According to Sun Pharmaceutical Industries Ltd’s financial statements for the past five years, the company has consistently increased its total sales, profit after tax (PAT), and overall profitability. The business has also had success controlling costs and keeping a strong profit margin. It is crucial to remember that sales growth and PAT increase have fluctuated in previous years.
The choice to invest in Sun Pharmaceutical Industries Ltd should be made after carefully evaluating the company’s financial and operational performance and taking into account any additional external factors that might have an impact on the pharmaceutical business. A financial counsellor should always be consulted before making any significant financial decision.
Leave a Reply